ELISA (EIA)
(Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 (MBS488488) to SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag and SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag from HEK293 cells. ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (blue line) or SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (orange line) from HEK293 cells (The Native Antigen Company) at concentrations of 5ug/ml. A 3-fold serial dilution from 125 ng/ml was performed using MBS488488. For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)
Mouse COVID 19 Spike S glycoprotein Coronavirus Monoclonal Antibody | anti-Covid-19 antibody
Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022]
ELISA (EIA)
(Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 (MBS488488) to SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag and SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag from HEK293 cells. ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (blue line) or SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (orange line) from HEK293 cells (The Native Antigen Company) at concentrations of 5ug/ml. A 3-fold serial dilution from 125 ng/ml was performed using MBS488488. For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)
ELISA (EIA)
(Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 (MBS488488) to SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag and SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag from HEK293 cells. ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (blue line) or SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (orange line) from HEK293 cells (The Native Antigen Company) at concentrations of 5ug/ml. A 3-fold serial dilution from 125 ng/ml was performed using MBS488488. For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)
ELISA (EIA)
(Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 (MBS488488) to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 of various origin. ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line), SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) and SARS Coronavirus Spike Glycoprotein (S1), His-Tag (HEK293 cells; blue line) (The Native Antigen Company) at concentrations of 5ug/ml. A 3-fold serial dilution from 41.6 ng/ml was performed using MBS488488. For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)
ELISA (EIA)
(Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 (MBS488488) to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 of various origin. ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line), SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) and SARS Coronavirus Spike Glycoprotein (S1), His-Tag (HEK293 cells; blue line) (The Native Antigen Company) at concentrations of 5ug/ml. A 3-fold serial dilution from 41.6 ng/ml was performed using MBS488488. For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)
ELISA (EIA)
(Binding curve of four different formats of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 (MBS488488) to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 (His-Tag (Insect Cells)). ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line) and SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) (Native Antigen) at concentrations of 5ug/ml. A 3-fold serial dilution from 41.6 ng/ml was performed using MBS488488; from 370 ng/ml for MBS488783 and from 10000 ng/ml for MBS488782 and MBS488488-11.0. Human IgM, human IgA and human IgG2 were HRP-conjugated and for the detection of human IgG1 a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)
ELISA (EIA)
(Binding curve of four different formats of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 (MBS488488) to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 (His-Tag (Insect Cells)). ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line) and SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) (Native Antigen) at concentrations of 5ug/ml. A 3-fold serial dilution from 41.6 ng/ml was performed using MBS488488; from 370 ng/ml for MBS488783 and from 10000 ng/ml for MBS488782 and MBS488488-11.0. Human IgM, human IgA and human IgG2 were HRP-conjugated and for the detection of human IgG1 a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)
ELISA (EIA)
(ELISA using CR3022 (MBS488488) and the Brazilian mutant Spike protein (B1.1.24 / P.1). The plate was coated with the mutant Spike protein P.1 (The Native Antigen Company) at 2.5ug/ml. MBS488488 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 3,000 ng/ml.)
ELISA (EIA)
(ELISA using CR3022 (MBS488488) and the Brazilian mutant Spike protein (B1.1.24 / P.1). The plate was coated with the mutant Spike protein P.1 (The Native Antigen Company) at 2.5ug/ml. MBS488488 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 3,000 ng/ml.)
The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
Note on publication: Describes the discovery and original characterization of this antibody.
NCBI and Uniprot Product Information
Uniprot Description
S1 attaches the virion to the cell membrane by interacting with human ACE2 and CLEC4M/DC-SIGNR, initiating the infection. Binding to the receptor and internalization of the virus into the endosomes of the host cell probably induces conformational changes in the S glycoprotein. Proteolysis by cathepsin CTSL may unmask the fusion peptide of S2 and activate membranes fusion within endosomes.
Research Articles on Covid-19
Similar Products
Product Notes
The Covid-19 s (Catalog #AAA488784) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022] reacts with SARS-CoV-2 (COVID-19) & SARS Coronavirus and may cross-react with other species as described in the data sheet. AAA Biotech's COVID 19 Spike S glycoprotein Coronavirus can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), NTRL, Surface Plasmon Resonance (SPR), Crystallography, Immunofluorescence (IF). This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of test assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Bates et al. 2021 (PMID: 32766589) used CR3022 in an immunofluorescence assay. Researchers should empirically determine the suitability of the Covid-19 s for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "COVID 19 Spike S glycoprotein Coronavirus, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
